Treatment of Headache Pain with Botulinum Neurotoxins

Pain Practice

Volumn 4, Issue , 2004, Pages S38-S46

  Tepper, Stewart J ^a,b  

^a NEW ENGLAND CENTER FOR HEADACHE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; CYPROHEPTADINE; GABAPENTIN; IBUPROFEN; METHYLERGOMETRINE; METOPROLOL; MUSCLE RELAXANT AGENT; PLACEBO; PROPRANOLOL; RIBOFLAVIN; TIMOLOL; TIZANIDINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VERAPAMIL;

ARTICLE; CHRONIC POSTTRAUMATIC HEADACHE; COMORBIDITY; DEMOGRAPHY; DRUG MECHANISM; EPILEPSY; HEADACHE; HEALTH CARE COST; HUMAN; MAJOR DEPRESSION; MIGRAINE; POSTTRAUMATIC HEADACHE; PREVALENCE; PRODUCTIVITY; QUALITY OF LIFE; TENSION HEADACHE; TRANSFORMED MIGRAINE;

EID: 18844426816     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2004.04013.x     Document Type: Article

References (38)

1. Silberstein SD, Rosenberg J. Multispecialty consensus on diagnosis and treatment of headache [special article]. Neurology. 2000;54: 1553.
2. National Headache Foundation. NHF: Headache facts. Available at: http://www.headaches.org/consumer/generalinfo/factsheet.html. Accessed August 6, 2003.
3. Beth Israel Medical Center Department of Pain Medicine and Palliative Care. Pain medicine. Available at: http://www.stoppain.org/pain_medicine/headache.html. Accessed August 6, 2003.
4. Rasmussen BK. Epidemiology of headache. Cephalalgia. 1995;15: 45-68.
5. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41: 646-657.
6. Lipton RB, Stewart WF, Von Korff M. Burden of migraine: societal costs and therapeutic opportunities. Neurology. 1997;48(suppl 3):S4-S9.
7. Smith C, Fraser MO, Bartho L, Degroat WC, Chancellor MB, Somogyi G. Botulinum toxin A inhibits afferent nerve evoked bladder strip contractions [abstract 164]. J Urol. 2002;167(suppl):41.
8. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267: 64-69.
9. Elkind AH, Kozma C, Reeder CE. Impact of chronic headache on quality of life, productivity, and morbidity [poster F11]. Presented at: 44th Annual Scientific Meeting of American Headache Society; June 21-23, 2002; Seattle, WA.
10. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159: 813-818.
11. Lipton RB, Silberstein SD. Why study the comorbidity of migraine? Neurology. 1994;44: S4-S5.
12. Breslau N, Merikangas K, Bowden CL. Comorbidity of migraine and major affective disorders. Neurology. 1994;44(suppl 7):S17-S22.
13. Breslau N, Davis GC, Schultz LR, Peterson EL. Joint 1994 Wolff Award Presentation. Migraine and major depression: a longitudinal study. Headache. 1994;34: 387-393.
14. Diener HC. New data evaluating the safety of triptans in rational approaches toward the improvement of diagnosis and management of migraine: latest evidence [oral presentation]. Presented at: XI Congress of the International Headache Society (IHC 2003), satellite symposium organized and sponsored by Pfizer; September 15, 2003; Rome, Italy.
15. Velentgas P, Cole A, Mo J, Walker AM. Triptan use is not associated with increased risk of severe vascular events in migraine patients [abstract]. Eur J Neurol. 2002;9(suppl 2):44.
16. National Institute of Neurological Disorders and Stroke. Migraine update. Available at: http://www.ninds.nih.gov/health_and_medical/pubs/migraineupdate.htm. Accessed August 11, 2003.
17. Goadsby PJ. Current concepts of the pathophysiology of migraine. Neurol Clin. 1997;15: 27-42.
18. National Institute of Neurological Disorders and Stroke. 21st century prevention and management of migraine headaches. Clinician. 2001;19: 1-26.
19. Ray BS, Wolff HG. Experimental studies on headaches, pain sensitive structures of the head and their significance in headaches. Arch Surg. 1940;41: 813-856.
20. Hargreaves RJ, Shepheard SL. Pathophysiology of migraine-new insights. Can J Neurol Sci. 1999;26(suppl 3):S12-S19.
21. Longmore J, Shaw D, Smith D, et al. Differential distribution of 5HTID- and 5HTIB-immunoreactivity within the human trigemino-cerebro vascular system: implications for the discovery of new antimigraine drugs. Cephalalgia. 1997;17: 833-842.
22. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H, Jr. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265: 2831-2835.
23. Gawel MJ, Kreeft J, Nelson RF, Simard D, Arnott WS. Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. Can J Neurol Sci. 1992;19: 340-345.
24. Geraud G, Olesen J, Pfaffenrath V, et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia. 2000;20: 30-38.
25. Jhee SS, Salazar DE, Ford NF, Fulmor IE, Sramek JJ, Cutler NR. Monitoring of acute migraine attacks: placebo response and safety data. Headache. 1998;38: 35-38.
26. Silberstein SD, Massiou H, Le Jeunne C, Johnson-Pratt L, McCarroll KA, Lines CR. Rizatriptan in the treatment of menstrual migraine. Obstet Gynecol. 2000;96: 237-242.
27. Steiner TJ, Lange R. Ketoprofen (25mg) in the symptomatic treatment of episodic tension-type headache: double-blind placebo-controlled comparison with acetaminophen (1000mg). Cephalalgia. 1998;18: 38-43.
28. Royal MA. The use of botulinum toxins in the management of pain and headache. Pain Practice. 2001;1: 215-235.
29. Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg. 2000;123: 669-676.
30. Krusz J. Intradermal botulinum toxin, type A, for cervicogenic migraine [abstract S109]. Headache. 2002;42: 405.
31. Coffield JA, Considine RV, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallett M, eds. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc.; 1994: 3-13.
32. Binder W, Brin MF, Blitzer A, Schenrock L, Diamond L. Botulinum toxin type A (BTX-A) for migraine: an open label assessment [abstract P4.104]. Mov Disord. 1998;13(suppl 2):241.
33. Barrientos N, Chana P. Efficacy and safety of botulinum toxin type A (Botox) in the prophylactic treatment of migraine [abstract S106]. Headache. 2002;42: 452.
34. Silberstein S, Mathew N, Saper J. For the BOTOX Migraine Clinical Research Group. Botulinum toxin type A as a migraine preventive treatment. Headache. 2000;40: 445-450.
35. Gwynn MW, Baker T, English J. Double-blind, placebo-controlled study of botulinum toxin B for the treatment of chronic headache [abstract 20030300491]. Available at: http://www.abstracts-on-line.com/abstracts/AAN. Accessed August 5, 2003.
36. Freund BJ, Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: a pilot study. Headache. 2000;40: 231-236.
37. Wheeler AH. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache. 1998;38: 468-471.
38. International Headache Society. The International Classification of Headache Disorders. Available at: http://216.25.100.131/ihscommon/guidelines/pdfs/ihc_II_main_no_print.pdf. Accessed October 14, 2003.